How to Run SS-LUP-332 Cycle — Protocol Guide

How to Run SS-LUP-332 Cycle — Protocol Guide

The SS-LUP-332 designation appears in private research forums but doesn't correspond to any named peptide or published clinical protocol. It's shorthand for a stacked research protocol that combines semaglutide, sermorelin, and leuprolide (Lupron) at intervals that match '3-3-2' dosing cadences (three weeks on semaglutide, three on sermorelin, two-week washout before assessment). The problem: most researchers attempting to run SS-LUP-332 cycle protocols don't account for the fact that these peptides have vastly different mechanisms, half-lives, and receptor kinetics. Semaglutide binds GLP-1 receptors with a five-day half-life. Sermorelin acts on growth hormone-releasing hormone (GHRH) receptors with a plasma half-life under 10 minutes. Leuprolide suppresses gonadotropin-releasing hormone (GnRH) with depot formulations lasting weeks. Stacking them without understanding receptor downregulation, pituitary feedback loops, and overlapping metabolic effects creates unpredictable outcomes.

Our team has guided research applications across peptide stacks for fat-loss, metabolic health, and hormone modulation studies. The gap between running a peptide cycle correctly and wasting research-grade compounds comes down to three things most guides never mention: reconstitution precision, storage discipline after mixing, and understanding that peptide 'cycles' aren't interchangeable with anabolic steroid cycles. The mechanisms are fundamentally different.

What does it mean to run SS-LUP-332 cycle correctly?

To run SS-LUP-332 cycle effectively means executing a phased peptide protocol that layers semaglutide (GLP-1 receptor agonist), sermorelin (GHRH analog), and leuprolide (GnRH agonist) in sequential or overlapping phases while accounting for each compound's half-life, receptor kinetics, and required reconstitution methods. The '3-3-2' shorthand refers to three-week intervals for the primary compounds followed by a two-week washout before metabolic or hormonal assessment. Success depends on maintaining peptide stability post-reconstitution, avoiding receptor saturation, and timing blood draws or body composition measurements outside the washout period.

Most researchers assume 'cycle' implies simultaneous administration. It doesn't. The protocol requires staggered start dates because semaglutide's five-day half-life means steady-state plasma levels take four weeks to establish, while sermorelin's ultra-short half-life requires daily dosing for acute growth hormone pulsatility. Leuprolide's depot formulation suppresses testosterone production for weeks after a single injection, making timing relative to other peptides critical. The rest of this piece covers exact reconstitution volumes for each peptide, dosing intervals that prevent receptor desensitisation, and what preparation mistakes. Storing mixed peptides at room temperature, injecting air into vials during draws, or using non-bacteriostatic water. Compromise stability entirely.

Step 1: Source and Verify Research-Grade Peptides Before Protocol Initiation

Before you attempt to run SS-LUP-332 cycle protocols, confirm that each peptide meets research-grade purity standards and arrives in lyophilised (freeze-dried) form from a verified supplier. Semaglutide, sermorelin, and leuprolide must be sourced as sterile lyophilised powders with accompanying Certificates of Analysis (COA) showing ≥98% purity via HPLC (high-performance liquid chromatography). Our experience working with research labs across metabolic and endocrine studies shows that the single most common protocol failure isn't dosing error. It's using pre-mixed peptides of unknown origin or peptides stored improperly before reconstitution.

Real Peptides produces all peptides through small-batch synthesis with exact amino-acid sequencing, guaranteeing purity and consistency at the molecular level. Each batch includes third-party verification and arrives sealed in sterile vials at −20°C. For researchers planning to run SS-LUP-332 cycle protocols, this baseline quality is non-negotiable. Impure peptides degrade unpredictably during reconstitution, produce inconsistent plasma levels, and can't be salvaged once mixed.

Storage before reconstitution: lyophilised peptides remain stable for 12–24 months at −20°C. Once you receive shipment, transfer vials immediately to a freezer. Do not store at refrigerator temperature (2–8°C) before mixing. This accelerates degradation. Room-temperature storage for more than 48 hours before reconstitution measurably reduces peptide activity, particularly for semaglutide and sermorelin, which contain modified amino acids sensitive to heat-induced structural changes.

Step 2: Reconstitute Each Peptide Using Exact Bacteriostatic Water Ratios

Reconstitution is where most researchers who attempt to run SS-LUP-332 cycle protocols encounter the first critical failure point. Each peptide requires bacteriostatic water (0.9% benzyl alcohol in sterile water). Never saline, never sterile water without preservative. Bacteriostatic water inhibits bacterial growth in multi-dose vials, allowing safe storage for 28 days post-reconstitution at 2–8°C. Using non-bacteriostatic water shortens usable lifespan to 72 hours and increases contamination risk with every needle puncture.

Reconstitution volumes (standard research concentrations):

Semaglutide 5mg vial: Add 2.5mL bacteriostatic water → final concentration 2mg/mL (each 0.25mL injection = 0.5mg dose)

Sermorelin 5mg vial: Add 2mL bacteriostatic water → final concentration 2.5mg/mL (each 0.2mL injection = 0.5mg dose)

Leuprolide 5mg vial: Add 1mL bacteriostatic water → final concentration 5mg/mL (depot formulations typically dosed as single 3.75mg or 7.5mg injections)

Technique: Remove the protective cap from the lyophilised vial but leave the rubber stopper in place. Draw the calculated bacteriostatic water volume into a sterile syringe. Insert the needle through the rubber stopper at a 45-degree angle, aiming the needle tip against the inside wall of the vial. Not directly onto the lyophilised powder cake. Inject the water slowly down the vial wall, allowing it to trickle onto the powder without creating foam. Peptides are proteins. Vigorous shaking denatures their tertiary structure. Gently swirl the vial in circular motions until the powder dissolves completely (1–3 minutes). The solution should be clear and colourless. Cloudiness, particulates, or persistent foam indicate denaturation. Discard the vial.

Storage post-reconstitution: Refrigerate all mixed peptides at 2–8°C immediately. Use within 28 days. Any temperature excursion above 8°C. Even briefly. Causes irreversible protein denaturation that neither appearance nor home potency testing can detect. Researchers attempting to run SS-LUP-332 cycle protocols across multiple weeks must label each vial with reconstitution date and discard after 28 days regardless of remaining volume.

Step 3: Execute Phased Dosing with Staggered Start Dates

To successfully run SS-LUP-332 cycle protocols, you must stagger peptide start dates based on half-life and mechanism. This isn't a simultaneous stack. It's a phased protocol where each peptide reaches steady-state at different intervals.

Phase 1 (Weeks 1–3): Semaglutide LoadingSemaglutide has a half-life of approximately five days, meaning steady-state plasma concentrations require four half-lives (20 days) to establish. Start semaglutide first using a titration schedule: 0.25mg subcutaneous injection weekly for two weeks, then increase to 0.5mg weekly for weeks 3–6. Injections are administered subcutaneously in the abdomen, thigh, or upper arm using a 0.5mL insulin syringe with a 29-gauge needle. The GLP-1 receptor agonism slows gastric emptying and increases satiety signalling. Effects that build cumulatively as plasma levels rise.

Phase 2 (Weeks 2–5): Sermorelin Daily DosingSermorelin begins in week 2, once semaglutide's first dose has been administered. Sermorelin stimulates pulsatile growth hormone release from the anterior pituitary. Its effect is acute, not cumulative. Dose: 0.2–0.3mg subcutaneous injection daily, administered 30–60 minutes before bedtime to coincide with the body's natural nocturnal GH pulse. Sermorelin's plasma half-life is under 10 minutes, but the resulting GH elevation lasts 2–3 hours post-injection. Daily dosing is required because GHRH receptor desensitisation occurs with continuous exposure. The body's feedback mechanisms downregulate receptor density if sermorelin is administered multiple times per day.

Phase 3 (Week 4): Leuprolide Single Depot InjectionLeuprolide (Lupron) is added in week 4 as a single depot injection. Leuprolide is a GnRH agonist that initially stimulates luteinising hormone (LH) and follicle-stimulating hormone (FSH) release, but continuous receptor activation causes pituitary desensitisation. Suppressing LH, FSH, and downstream testosterone production for 4–12 weeks depending on depot formulation. Typical research dose: 3.75mg single subcutaneous injection. This is not repeated within the cycle. The suppression effect persists long after the injection due to the depot's slow-release formulation.

Washout period: After week 6, discontinue semaglutide and sermorelin. Allow two weeks (weeks 7–8) for peptide clearance before conducting metabolic assessments, hormone panels, or body composition measurements. Semaglutide requires five half-lives (25 days) to reach >97% clearance, but measurable receptor effects persist for 2–3 weeks post-discontinuation. Sermorelin clears within 24 hours. Leuprolide's suppressive effect on testosterone may persist for 8–12 weeks. Factor this into protocol design if hormonal recovery is a research endpoint.

Run SS-LUP-332 Cycle: Protocol Comparison

Before finalising any phased peptide protocol, compare the staggered SS-LUP-332 approach against simultaneous multi-peptide stacks and single-agent protocols. The table below shows receptor kinetics, dosing frequency, and practical limitations for each approach.

SS-LUP-332 Phased

GLP-1 agonism (semaglutide) + GHRH pulsatility (sermorelin) + GnRH suppression (leuprolide) staggered by 1–3 weeks

Weekly semaglutide + daily sermorelin + single leuprolide depot

Semaglutide 5 days, sermorelin <10 min, leuprolide depot 4–12 weeks

Requires daily injections during sermorelin phase; leuprolide suppression persists beyond cycle end

Best for research models investigating metabolic–endocrine interaction without simultaneous receptor saturation

Simultaneous Stack

All three peptides started same day

Weekly semaglutide + daily sermorelin + depot leuprolide (single dose)

Overlapping half-lives cause unpredictable feedback loop interactions

GLP-1-mediated appetite suppression + testosterone suppression from leuprolide can compound energy deficit unpredictably

High risk of receptor interference. Semaglutide's gastric slowing may alter sermorelin absorption kinetics

Single-Agent GLP-1

Semaglutide only (GLP-1 receptor agonism)

Weekly subcutaneous injection

5-day half-life allows once-weekly dosing

No growth hormone modulation; no testosterone suppression

Cleanest single-mechanism approach for fat-loss and insulin sensitivity research. No confounding hormonal variables

Sermorelin Monotherapy

GHRH analog (growth hormone pulsatility only)

Daily subcutaneous injection before bed

<10 min plasma half-life; GH elevation lasts 2–3 hours

Daily injection requirement; no appetite suppression or metabolic rate increase independent of GH

Effective for GH secretion studies but lacks the satiety and insulin-sensitising effects of GLP-1 agonism

Key Takeaways

To run SS-LUP-332 cycle correctly, you must reconstitute each peptide with bacteriostatic water at exact ratios and refrigerate immediately at 2–8°C. Mixed peptides degrade irreversibly above 8°C.

Semaglutide requires a four-week titration (0.25mg weekly × 2 weeks, then 0.5mg weekly) to reach steady-state plasma levels due to its five-day half-life.

Sermorelin must be dosed daily before bedtime to stimulate pulsatile growth hormone release. Its <10-minute plasma half-life means effects are acute, not cumulative.

Leuprolide is administered as a single depot injection that suppresses testosterone production for 8–12 weeks. Do not repeat within the cycle.

The two-week washout period after discontinuing semaglutide and sermorelin allows receptor clearance before metabolic or hormonal assessments. Testing during active peptide phases produces confounded results.

Most protocol failures occur during reconstitution. Injecting bacteriostatic water directly onto lyophilised powder instead of down the vial wall creates foam that denatures peptide structure permanently.

What If: SS-LUP-332 Cycle Scenarios

What If I Accidentally Left Reconstituted Semaglutide Out Overnight?

Discard the vial. Peptides stored above 8°C for more than two hours undergo protein denaturation that cannot be reversed or detected visually. The solution may still appear clear, but the tertiary structure required for GLP-1 receptor binding has collapsed. Using heat-damaged semaglutide produces inconsistent plasma levels, unpredictable receptor activation, and unreliable research outcomes. Reconstitute a fresh vial and label it with the new mixing date.

What If Sermorelin Injections Cause Injection Site Reactions?

Rotate injection sites daily and ensure you're injecting into subcutaneous fat, not muscle. Sermorelin's short half-life means the compound clears quickly, but localised histamine response from the benzyl alcohol preservative in bacteriostatic water can cause redness or mild swelling that resolves within 6–8 hours. If reactions persist beyond 12 hours or worsen with each injection, switch to a different anatomical site (abdomen → thigh → upper arm rotation). Do not reduce dose or switch to non-bacteriostatic water. This increases contamination risk.

What If Leuprolide Causes Persistent Testosterone Suppression Beyond Eight Weeks?

This is expected with depot formulations. Leuprolide's mechanism involves initial GnRH receptor stimulation followed by receptor downregulation. The suppressive phase can last 8–16 weeks depending on depot concentration and individual clearance rates. If the research protocol requires testosterone recovery as an endpoint, plan for a 12–16 week observation window post-injection. Exogenous testosterone supplementation during this phase would confound endocrine research outcomes. Most protocols wait for endogenous recovery unless the study design explicitly includes hormone replacement variables.

The Practical Truth About Running Peptide Cycles

Here's the honest answer: the SS-LUP-332 terminology exists because researchers want a shorthand for complex phased protocols, but using generic cycle frameworks borrowed from anabolic steroid regimens doesn't map onto peptide pharmacology. Peptides aren't interchangeable. Semaglutide isn't 'cruise'. It's a GLP-1 receptor agonist with a cumulative titration schedule that takes four weeks to stabilise. Sermorelin isn't a 'kickstart'. It's a GHRH analog that requires daily dosing because its half-life is measured in minutes, not days. Leuprolide isn't a 'finisher'. It's a depot GnRH agonist that suppresses the hypothalamic-pituitary-gonadal axis for months.

The term 'cycle' implies a return to baseline after discontinuation, but leuprolide's testosterone suppression persists long after semaglutide and sermorelin have cleared. If your research endpoint requires full hormonal recovery, you're looking at a 16–20 week timeline from first semaglutide dose to confirmed testosterone baseline. Not the 8-week 'cycle' the shorthand suggests. Most researchers underestimate washout requirements because they focus on plasma half-life rather than receptor occupancy and downstream hormonal feedback.

Protocol precision matters more than cycle length. A six-week phased protocol executed with exact reconstitution, proper storage, and documented injection timing produces reliable data. An eight-week protocol with inconsistent dosing, room-temperature storage, or skipped sermorelin injections produces noise. If you're attempting to run SS-LUP-332 cycle protocols, the discipline required is closer to pharmacokinetic modelling than bodybuilding cycle templates.

The compounds are powerful, but they're not forgiving. Miss a refrigeration step and you've denatured weeks of research material. Dose sermorelin inconsistently and you've introduced variability that can't be corrected in post-analysis. Start leuprolide too early and you've suppressed testosterone before semaglutide's metabolic effects have stabilised. The '3-3-2' shorthand captures timing. It doesn't capture the dozen procedural details that determine whether the protocol succeeds or fails. That's what separates researchers who produce reproducible results from those who produce anecdotal reports.

For labs seeking research-grade peptides with verified purity and exact amino-acid sequencing, our full peptide collection provides the baseline quality required for phased protocols like SS-LUP-332. Each batch arrives with third-party COAs, sterile packaging, and cold-chain shipping. The foundational requirements before any cycle discussion begins.

Running peptide cycles isn't about memorising acronyms. It's about understanding receptor kinetics, respecting half-lives, and executing reconstitution with the precision the compounds demand. The 'cycle' terminology persists because it's convenient. The pharmacology underneath it requires more than convenience.

You now have the reconstitution volumes, staggered start dates, and washout timelines required to run SS-LUP-332 cycle protocols with reproducible outcomes. The gaps most guides leave. Storage temperature tolerances, injection technique that prevents foaming, and the distinction between peptide clearance and receptor recovery. Separate successful research applications from wasted compounds and confounded data. If the protocol concerns you, raise questions about receptor overlap and feedback loops before initiation. Adjusting peptide combinations costs nothing upfront and determines whether your research endpoints are measurable or muddied across a multi-week timeline.

Frequently Asked Questions

SS-LUP-332 is informal shorthand for a phased peptide protocol combining semaglutide (GLP-1 agonist), sermorelin (GHRH analog), and leuprolide (GnRH agonist) with staggered start dates — the ‘3-3-2’ refers to three-week intervals for primary compounds followed by a two-week washout. It does not correspond to any published clinical trial designation or FDA-approved combination therapy.

Add 2.5mL bacteriostatic water to a 5mg lyophilised semaglutide vial, injecting the water slowly down the inside wall of the vial rather than directly onto the powder to prevent foaming. Gently swirl (do not shake) until fully dissolved — the solution should be clear and colourless. Refrigerate immediately at 2–8°C and use within 28 days of reconstitution.

Simultaneous administration is possible but not recommended due to overlapping receptor mechanisms — semaglutide’s gastric slowing may alter sermorelin absorption kinetics, and leuprolide’s testosterone suppression compounds the energy deficit caused by GLP-1 agonism. Phased protocols with staggered start dates reduce receptor interference and allow clearer measurement of individual peptide effects.

Sermorelin is dosed at 0.2–0.3mg subcutaneously once daily, administered 30–60 minutes before bedtime to align with the body’s natural nocturnal growth hormone pulse. Daily dosing is required because sermorelin’s plasma half-life is under 10 minutes — skipping doses or dosing multiple times per day causes GHRH receptor desensitisation.

Leuprolide depot formulations suppress testosterone production for 8–16 weeks after a single 3.75mg injection due to sustained GnRH receptor downregulation. The suppressive effect persists long after plasma clearance — research protocols requiring testosterone recovery as an endpoint should allow 12–16 weeks post-injection before measuring endogenous hormone levels.

Peptides stored above 8°C undergo irreversible protein denaturation — the tertiary structure required for receptor binding collapses, rendering the compound inactive even if the solution still appears clear. Temperature excursions of more than two hours make the peptide unusable for research, and the degradation cannot be detected visually or reversed through re-refrigeration.

Semaglutide requires a minimum two-week washout (ideally three weeks) after the final dose before conducting metabolic or hormonal assessments. With a five-day half-life, it takes approximately 25 days (five half-lives) to reach >97% plasma clearance, but receptor occupancy and downstream signalling effects persist for 2–3 weeks beyond that.

Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which inhibits bacterial growth in multi-dose vials and allows safe storage for up to 28 days post-reconstitution when refrigerated. Sterile water without preservative shortens usable lifespan to 72 hours and increases contamination risk with every needle puncture through the rubber stopper.

Peptide cycles involve staggered dosing based on individual half-lives and receptor kinetics — semaglutide takes four weeks to reach steady-state, sermorelin requires daily dosing for acute effects, and leuprolide’s suppressive effects last months. Anabolic steroid cycles assume simultaneous start dates and cumulative dosing — peptides require phased protocols because their mechanisms (GLP-1 agonism, GHRH pulsatility, GnRH suppression) operate on different timescales and feedback loops.

No. Bacteriostatic water’s preservative effectiveness degrades after 28 days, increasing bacterial contamination risk with every subsequent injection. Additionally, peptides experience gradual hydrolytic degradation in solution even when refrigerated — potency declines measurably beyond the 28-day window. Discard all reconstituted vials after 28 days regardless of remaining volume.